# A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)

> **NCT06658626** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [¹⁴C]Enlicitide chloride

## Key facts

- **NCT ID:** NCT06658626
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-10
- **Primary completion:** 2023-08-02
- **Final completion:** 2023-08-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06658626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06658626, "A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06658626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*